Table 2.
Anti-DENV neutralization patterns* at enrollment | Age in years, n (%) | Total | |||
---|---|---|---|---|---|
10–11 | 12–13 | 14–15 | 16–18 | ||
Negative for anti-DENV IgG† | 8 (15.4) | 8 (16.5) | 7 (32.7) | 3 (15.4) | 26 (19.6)‡ |
Past DENV infection, single serotype | 15 (28.5) | 14 (25.7) | 9 (26.1) | 8 (30.6) | 46 (27.5)§ |
DENV-1¶ | 0 | 1 (12.2) | 0 | 2 (19.5) | 3 (7.4)∥ |
DENV-2¶ | 1 (4.9) | 6 (42.2) | 2 (18.1) | 1 (9.8) | 10 (19.9)** |
DENV-3¶ | 11 (75.3) | 5 (37.3) | 5 (47.5) | 3 (51.1) | 24 (53.8)†† |
DENV-4¶ | 3 (19.7) | 2 (8.3) | 2 (34.3) | 2 (19.6) | 9 (18.9)‡‡ |
Past DENV infection, serotype undetermined | 29 (56.1) | 33 (57.8) | 17 (41.3) | 19 (53.9) | 98 (52.9)§§ |
Total | 52 | 55 | 33 | 30 | 170 |
Calibration weighting was applied to the calculation of all proportions.
MNT was used to detect anti-DENV neutralization antibodies in enrollment specimens with a positive IgG anti-DENV ELISA result.
Enrollment specimens with a negative single-dilution (1:100) IgG anti-DENV ELISA result did not receive additional testing.
95% CI = 13.6–27.4%.
95% CI = 13.6–27.4%.
Predominant serotype; numbers in parentheses represent the percentages of the total for that past single-serotype DENV infection pattern by age group.
95% CI = 3.2–16.3%.
95% CI = 10.5–34.3%.
95% CI = 40.4–66.6%.
95% CI = 10.2–32.4%.
95% CI = 46.5–59.3%.